Clinical Trial Detail

NCT ID NCT02193282
Title Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Erlotinib

Age Groups: adult senior

No variant requirements are available.